Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales.
Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG
Get this delivered to your inbox, and more info about our products and services.
Novo Nordisk CEO Mike Doustdar discusses the pharma giant's Q4 reporting, uptake of obesity drugs and how he plans to navigate…
Novo Nordisk CEO Mike Doustdar told Jim Cramer about developments in obesity treatment.
"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around…
The early data is a boost to the Danish drugmaker's hopes of winning back more market share from Eli Lilly this year in the…
The Wegovy obesity drug maker on Wednesday announced plans to trim 11.5% of its workforce.
